Analysts' ratings for IDEAYA Biosciences IDYA over the last quarter vary from bullish to bearish, as provided by 8 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 5 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 2 | 0 | 0 | 0 |
| 3M Ago | 1 | 2 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $44.5, a high estimate of $53.00, and a low estimate of $36.00. Marking an increase of 16.49%, the current average surpasses the previous average price target of $38.20.
Understanding Analyst Ratings: A Comprehensive Breakdown
The standing of IDEAYA Biosciences among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Corinne Jenkins | Goldman Sachs | Raises | Buy | $53.00 | $36.00 |
| Corinne Jenkins | Goldman Sachs | Raises | Buy | $53.00 | $36.00 |
| Gregory Renza | RBC Capital | Raises | Outperform | $43.00 | $36.00 |
| Gregory Renza | RBC Capital | Maintains | Outperform | $36.00 | - |
| Anupam Rama | JP Morgan | Raises | Overweight | $41.00 | $35.00 |
| Robert Driscoll | Wedbush | Maintains | Outperform | $43.00 | - |
| Vanck Zhu | Guggenheim | Lowers | Buy | $44.00 | $48.00 |
| Robert Driscoll | Wedbush | Maintains | Outperform | $43.00 | - |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to IDEAYA Biosciences. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of IDEAYA Biosciences compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of IDEAYA Biosciences's stock. This analysis reveals shifts in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of IDEAYA Biosciences's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on IDEAYA Biosciences analyst ratings.
About IDEAYA Biosciences
IDEAYA Biosciences Inc an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.
Financial Milestones: IDEAYA Biosciences's Journey
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Negative Revenue Trend: Examining IDEAYA Biosciences's financials over 3 months reveals challenges. As of 30 September, 2023, the company experienced a decline of approximately -72.94% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: IDEAYA Biosciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -341.38%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -5.44%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): IDEAYA Biosciences's ROA stands out, surpassing industry averages. With an impressive ROA of -5.17%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: IDEAYA Biosciences's debt-to-equity ratio is below the industry average. With a ratio of 0.0, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analyst Ratings: What Are They?
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
